Get the Stockscreener App
42.83
0.58%
-0.25
After Hours:
42.82
-0.010
-0.02%
Rigel Pharmaceuticals stock is traded at $42.83, with a volume of 1.05M.
It is down -0.58% in the last 24 hours and down -15.17% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$43.08
Open:
$42.91
24h Volume:
1.05M
Relative Volume:
1.79
Market Cap:
$777.42M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-305.93
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
-2.53%
1M Performance:
-15.17%
6M Performance:
+119.87%
1Y Performance:
+160.05%
1-Day Range:
$41.54
$42.91
1-Week Range:
$41.54
$44.85
52-Week Range:
$15.50
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
42.83 | 781.96M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Range Financial Group LLC Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
With EPS Growth And More, Rigel Pharmaceuticals (NASDAQ:RIGL) Makes An Interesting Case - Yahoo Finance
Inspire Investing LLC Makes New $859,000 Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Momentum Shift: Will Rigel Pharmaceuticals Inc RI2 stock beat Nasdaq index returnsInsider Selling & Free Growth Oriented Trading Recommendations - moha.gov.vn
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 23% Below Their Intrinsic Value Estimate - 富途牛牛
Assenagon Asset Management S.A. Decreases Holdings in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
(RIGL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Rigel Pharmaceuticals (NASDAQ:RIGL) Upgraded to Buy at Wall Street Zen - MarketBeat
Rigel Pharmaceuticals jumps on 2025 revenue guidance boost, Q3 beats - MSN
Can Rigel Pharmaceuticals Inc. stock deliver sustainable ROEJuly 2025 Snapshot & Weekly High Return Opportunities - Улправда
Will Rigel Pharmaceuticals Inc. stock benefit from automationEarnings Growth Report & Consistent Growth Stock Picks - DonanımHaber
How Rigel Pharmaceuticals Inc. stock compares to market leadersJuly 2025 Breakouts & High Accuracy Trade Alerts - DonanımHaber
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Is Rigel Pharmaceuticals Inc. stock near bottom after declineQuarterly Profit Review & Verified Short-Term Plans - Улправда
Rigel Pharmaceuticals announces updated data from Phase 1b study of R2891 - MSN
Rigel Pharmaceuticals Earnings Notes - Trefis
Rigel Pharmaceuticals reports promising Phase 1b study results - MSN
Behavioral Patterns of RIGL and Institutional Flows - news.stocktradersdaily.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Rigel Pharma downgraded by Piper Sandler with a new price target - Quantisnow
Insiders Who Sold Rigel Pharmaceuticals Made The Right Call As Market Cap Slides By US$97m - simplywall.st
Rigel Pharmaceuticals, Inc. $RIGL Shares Bought by Globeflex Capital L P - MarketBeat
Armistice Capital LLC Acquires 84,000 Shares of Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Top-Rated Stocks: Rigel Pharmaceuticals Sees Composite Rating Climb To 96 - MSN
Rigel Pharmaceuticals Reports Promising Phase 1b Study Results - TipRanks
Rigel Pharmaceuticals Inc Presents Updated Data from Phase 1b Study on R289 - TradingView — Track All Markets
Rigel Pharmaceuticals Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading Down 13.7%Should You Sell? - MarketBeat
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals (RIGL) is a great momentum stock: Should you buy? - MSN
Rigel Pharmaceuticals (RIGL) Shares Promising Data from Phase 1b Study - GuruFocus
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition - Lelezard
How the Narrative Surrounding Rigel Pharmaceuticals Is Shifting After Upgraded Targets and Guidance - Yahoo Finance
Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy? - sharewise.com
Why Rigel Pharmaceuticals Inc. (RI2) stock could break out in 2025July 2025 Analyst Calls & Daily Profit Maximizing Trade Tips - Newser
Is Rigel Pharmaceuticals Inc. (RI2) stock supported by free cash flowTrade Analysis Report & Long-Term Safe Return Strategies - Newser
Will Rigel Pharmaceuticals Inc. (RI2) stock split increase liquidityWeekly Trade Review & Free High Accuracy Swing Entry Alerts - Newser
Why pension funds invest in Rigel Pharmaceuticals Inc. (RI2) stock2025 Year in Review & Verified Stock Trade Ideas - Newser
Will Rigel Pharmaceuticals Inc. (RI2) stock enhance shareholder valueMarket Sentiment Report & AI Based Trade Execution Alerts - Newser
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock? - sharewise.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading Down 6.1%Time to Sell? - MarketBeat
Will Rigel Pharmaceuticals Inc. (RI2) stock outperform small cap peers2025 Market Overview & Weekly High Potential Stock Alerts - Newser
(RIGL) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Would You Still Hold Rigel Pharmaceuticals Stock If It Fell Another 30%? - Trefis
Is Rigel Pharmaceuticals Inc. (RI2) stock a top dividend aristocrat candidatePortfolio Performance Report & Long-Term Investment Growth Plans - Newser
Is Rigel Pharmaceuticals Inc. (RI2) stock a buy before new product rolloutWeekly Market Summary & Stock Market Timing Techniques - Newser
Rigel Pharmaceuticals (RIGL) Stock Analysis Report | Financials & Insights - Benzinga
Can Rigel Pharmaceuticals Inc. (RI2) stock ride next bull market cycleTake Profit & Long-Term Capital Growth Strategies - Newser
Is Rigel Pharmaceuticals Inc. stock a buy for dividend growthMarket Performance Summary & Verified Technical Signals - Newser
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):